Jukka Westermarck
MD, PhD
jukka.westermarck@utu.fi +358 29 450 2880 +358 40 742 3007 Tykistökatu 6 Turku Työhuone: 4124 (B-stairs, 4th floor) ORCID-tunniste: https://orcid.org/0000-0001-7478-3018 |
Role and regulation of phosphatases, particularly tumor suppressor protein phosphatase 2A (PP2A) in human cancers
Jukka Westermarck is a Professor of Cancer Biology, and Research Director, in the Turku Bioscience Centre at University of Turku.
Westermarck earned his medical degree from University of Turku in 1996. Two years later he obtained his PhD degree in Department of Medical Biochemistry and Department of Dermatology at the same University. He was working as a postdoctoral fellow in the laboratory of Dirk Bohmann during 1999-2001 in the European Molecular Biology Laboratory in Heidelberg, Germany. After being appointed as Academy Fellow by the Academy of Finland, he established his own research group at Turku Centre for Biotechnology in 2002. In 2006-2009 he was appointed as a group leader in the Institute of Medical Technology at University of Tampere, and after that he returned back to Turku due to his appointment as a tenure Research Director of Turku Centre for Biotechnology, and as a Professor of Cancer Biology at the Faculty of Medicine. In 2012, he worked as a visiting Professor at Dana-Farber Cancer Institute, Boston.
Professor Westermarck received young researcher prize from Finnish Medical Association Duodecim 2007, and Anders Jahre young investigator prize 2009 from University of Oslo, Norway. In 2017, he became an elected member of the Finnish Academy of Science and Letters.
Prof. Westermarck´s research focuses on role and regulation of phosphatases, particularly tumor suppressor protein phosphatase 2A (PP2A) in human cancers. Based on this work his group has identified several novel signaling principles how PP2A regulates cancer progression, as well as potential novel cancer therapy targets and diagnostic biomarkers.
- Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinoma (2022)
- Oral Oncology
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Development of actionable targets of multi-kinase inhibitors (AToMI) screening platform to dissect kinase targets of staurosporines in glioblastoma cells (2022)
- Scientific Reports
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246-Sensitive Disease Subtype (2022)
- Molecular Cancer Therapeutics
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - SHARPIN S146 phosphorylation mediates ARP2/3 interaction, cancer cell invasion and metastasis (2022)
- Journal of Cell Science
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Cancer cell line microarray as a novel screening method for identification of radioresistance biomarkers in head and neck squamous cell carcinoma (2021)
- BMC Cancer
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Cancer stem cell phosphatases (2021)
- Biochemical Journal
(A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä) - CIP2A interacts with TopBP1 and drives basal-like breast cancer tumorigenesis (2021)
- Cancer Research
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Circumventing drug treatment? Intrinsic lethal effects of polyethyleneimine (PEI)-functionalized nanoparticles on glioblastoma cells cultured in stem cell conditions (2021)
- Cancers
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias (2021)
- Clinical Cancer Research
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Druggable cancer phosphatases (2021)
- Science Translational Medicine
(A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä)



